69 related articles for article (PubMed ID: 22480875)
21. CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells.
Schabath H; Runz S; Joumaa S; Altevogt P
J Cell Sci; 2006 Jan; 119(Pt 2):314-25. PubMed ID: 16390867
[TBL] [Abstract][Full Text] [Related]
22. Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation.
Bharadwaj U; Li M; Zhang R; Chen C; Yao Q
Cancer Res; 2007 Jun; 67(11):5479-88. PubMed ID: 17545630
[TBL] [Abstract][Full Text] [Related]
23. Human dendritic cell mediated cytotoxicity against breast carcinoma cells in vitro.
Manna PP; Mohanakumar T
J Leukoc Biol; 2002 Aug; 72(2):312-20. PubMed ID: 12149422
[TBL] [Abstract][Full Text] [Related]
24. Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis.
Afonja O; Juste D; Das S; Matsuhashi S; Samuels HH
Oncogene; 2004 Oct; 23(49):8135-45. PubMed ID: 15361828
[TBL] [Abstract][Full Text] [Related]
25. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
Chan T; Sami A; El-Gayed A; Guo X; Xiang J
Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
[TBL] [Abstract][Full Text] [Related]
26. Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12.
Chen Y; Emtage P; Zhu Q; Foley R; Muller W; Hitt M; Gauldie J; Wan Y
Gene Ther; 2001 Feb; 8(4):316-23. PubMed ID: 11313806
[TBL] [Abstract][Full Text] [Related]
27. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
[TBL] [Abstract][Full Text] [Related]
28. Characterizing the HER2/neu status and metastatic potential of breast cancer stem/progenitor cells.
Pommier SJ; Quan GG; Christante D; Muller P; Newell AE; Olson SB; Diggs B; Muldoon L; Neuwelt E; Pommier RF
Ann Surg Oncol; 2010 Feb; 17(2):613-23. PubMed ID: 19838757
[TBL] [Abstract][Full Text] [Related]
29. Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice.
Sas S; Chan T; Sami A; El-Gayed A; Xiang J
Cancer Gene Ther; 2008 Oct; 15(10):655-66. PubMed ID: 18421311
[TBL] [Abstract][Full Text] [Related]
30. Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells.
Brossart P; Zobywalski A; Grünebach F; Behnke L; Stuhler G; Reichardt VL; Kanz L; Brugger W
Cancer Res; 2000 Aug; 60(16):4485-92. PubMed ID: 10969796
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.
Rentzsch C; Kayser S; Stumm S; Watermann I; Walter S; Stevanoviç S; Wallwiener D; Gückel B
Clin Cancer Res; 2003 Oct; 9(12):4376-86. PubMed ID: 14555509
[TBL] [Abstract][Full Text] [Related]
32. [Specific cytotoxicity of CTL which was induced by DC pulsed with mannosylated antigen].
Zhong GC; Xu M; Shi M; Hu MR; Min M; Chen J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Feb; 23(2):117-9. PubMed ID: 17286902
[TBL] [Abstract][Full Text] [Related]
33. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
[TBL] [Abstract][Full Text] [Related]
34. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
[TBL] [Abstract][Full Text] [Related]
35. Down-regulation of HER-2 expression in human breast cancer cell HBC-4 and ZR75-1 by nitrogen-mustard-N-oxide.
Sai S; Furuya Y; Fujino Y; Kuroda Y
Kobe J Med Sci; 2007; 53(4):135-42. PubMed ID: 17932452
[TBL] [Abstract][Full Text] [Related]
36. Cord blood stem-cell-derived dendritic cells generate potent antigen-specific immune responses and anti-tumour effects.
Chang MC; Lee CN; Chen YL; Chiang YC; Sun WZ; Hu YH; Chen CA; Cheng WF
Clin Sci (Lond); 2012 Sep; 123(6):347-60. PubMed ID: 22264240
[TBL] [Abstract][Full Text] [Related]
37. IFN-beta inhibits human Th17 cell differentiation.
Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S
J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688
[TBL] [Abstract][Full Text] [Related]
38. Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA.
Sagiv E; Starr A; Rozovski U; Khosravi R; Altevogt P; Wang T; Arber N
Cancer Res; 2008 Apr; 68(8):2803-12. PubMed ID: 18413748
[TBL] [Abstract][Full Text] [Related]
39. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
Ram TG; Schelling ME; Hosick HL
Cell Growth Differ; 2000 Mar; 11(3):173-83. PubMed ID: 10768865
[TBL] [Abstract][Full Text] [Related]
40. HER2/neu antisense targeting of human breast carcinoma.
Roh H; Pippin JA; Green DW; Boswell CB; Hirose CT; Mokadam N; Drebin JA
Oncogene; 2000 Dec; 19(53):6138-43. PubMed ID: 11156527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
